What did the TRDA-related trust purchase in this Form 4 filing?

A revocable living trust associated with Entrada Therapeutics (TRDA) director Bernhardt G. Zeiher bought 5,000 common shares. The transaction was an open-market purchase reported as indirect ownership through the trust rather than personal direct holdings.

Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Entrada Therapeutics director-related trust buys shares. A revocable living trust associated with director Bernhardt G. Zeiher purchased 5,000 shares of Entrada Therapeutics common stock in an open-market transaction at a weighted average price of $5.8632 per share, with trade prices ranging from $5.86 to $6.00. Following the purchase, the trust holds 5,000 shares indirectly, and Dr. Zeiher disclaims beneficial ownership beyond any pecuniary interest.

Insider Trade Summary

Net Buyer: 5,000 shares ($29,316)

Net Buy 1 txn

Insider Zeiher Bernhardt G

Role null

Bought 5,000 shs ($29K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$5.8632	$29K

Holdings After Transaction: Common Stock — 5,000 shares (Indirect, By Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement)

Footnotes (1)

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Key Figures

Shares purchased: 5,000 shares Weighted average price: $5.8632 per share Price range: $5.86–$6.00 per share +1 more

4 metrics

Shares purchased 5,000 shares Open-market purchase of Entrada Therapeutics common stock

Weighted average price $5.8632 per share Average price for the 5,000-share purchase

Price range $5.86–$6.00 per share Range of prices across multiple purchase executions

Shares owned after transaction 5,000 shares Indirectly held by revocable living trust following purchase

Key Terms

open-market purchase, weighted average price, beneficial ownership, Revocable Living Trust Agreement

4 terms

open-market purchase financial

"reported as an open-market purchase of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Revocable Living Trust Agreement financial

"By Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement"

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeiher Bernhardt G

(Last)

(First)

(Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/20/2026		P		5,000	A	$5.8632⁽¹⁾	5,000	I	By Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

At what price did the TRDA trust buy the 5,000 shares?

The trust bought 5,000 Entrada Therapeutics (TRDA) shares at a weighted average price of $5.8632. Individual trades occurred in a price range from $5.86 to $6.00 per share, according to the Form 4 footnote disclosure.

How many TRDA shares does the trust hold after this transaction?

After this Form 4 transaction, the revocable living trust associated with Entrada Therapeutics (TRDA) director Bernhardt G. Zeiher holds 5,000 common shares indirectly. The filing lists 5,000 shares as the total ownership following the reported open-market purchase.

Is the TRDA director deemed to beneficially own the purchased shares?

The Form 4 states that Bernhardt G. Zeiher disclaims beneficial ownership of the Entrada Therapeutics (TRDA) shares held by the trust, except to the extent of any pecuniary interest. This means legal reporting is through the trust rather than as direct personal holdings.

What type of transaction is reported in this TRDA Form 4?

The filing reports an open-market purchase of Entrada Therapeutics (TRDA) common stock by a revocable living trust. The transaction code is “P,” indicating a standard purchase, and it is classified as indirect ownership on behalf of director Bernhardt G. Zeiher.

Were the TRDA shares bought in a single trade or multiple trades?

The shares were bought in multiple trades within a narrow price range. The Form 4 notes that the 5,000 Entrada Therapeutics (TRDA) shares were purchased in several transactions at prices from $5.86 to $6.00, resulting in a weighted average of $5.8632.